Login to Your Account



Search

Search results

Clinic Roundup

• TapImmune Inc. , of Seattle, said an interim safety analysis of the first five breast cancer patients treated with HER2/neu Class II antigens did not show any serious adverse events, so treatment of the remaining 17 patients in the Phase I st ...

BioWorld Today - Staff - 2013-01-10 01:00 - 0 comments - 0 attachments

Clinic Roundup

Biogen Idec Inc. , of Weston, Mass., and Swedish Orphan Biovitrum AB , of Stockholm, Sweden, disclosed positive results from A-LONG, a Phase III trial that evaluated a long-lasting clotting factor candidate in people with hemophilia A. (B ...

BioWorld Today - Staff - 2013-12-06 01:00 - 0 comments - 0 attachments

Clinic Roundup

Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer demonstrated a 20.7 month median overall survival (OS) in a single-arm Phase II tria ...

BioWorld Today - Staff - 2011-08-25 00:00 - 0 comments - 0 attachments

Clinic Roundup

• Galectin Therapeutics Inc. , of Norcross, Ga., said five of the eight patients have been enrolled and infused in the first cohort of its blinded Phase 1 trial of GR-MD-02 for patients with nonalcoholic steatohepatitis (NASH or fatty liver disease) ...

BioWorld Today - Staff - 2013-11-13 01:00 - 0 comments - 0 attachments

Clinic Roundup

No Abstract (BioWorld Today, BioWorld-Today-2006-05-16) ...

BioWorld Today - Staff - 2006-05-16 00:00 - 0 comments - 0 attachments

Clinic Roundup

No Abstract (BioWorld Today, BioWorld-Today-2007-10-02) ...

BioWorld Today - Staff - 2007-10-02 00:00 - 0 comments - 0 attachments

Clinic Roundup

• Cel-Sci Corp. , of Vienna, Va., said a second interim review of the safety data from its open-label, randomized, Phase III study of immunotherapy candidate Multikine (leukocyte interleukin, injection) was conducted, with the independent data monito ...

BioWorld Today - Staff - 2013-11-06 01:00 - 0 comments - 0 attachments

Clinic Roundup

• TapImmune Inc. , of Seattle, said the Mayo Clinic received investigational new drug application allowance for a Phase I trial of the company's HER-2/neu vaccine in breast cancer patients who finished standard Herceptin (trastuzumab, Roche AG)-bas ...

BioWorld Today - Staff - 2012-05-07 00:00 - 0 comments - 0 attachments

Clinic Roundup

No Abstract (BioWorld Today, BioWorld-Today-2006-07-06) ...

BioWorld Today - Staff - 2006-07-06 00:00 - 0 comments - 0 attachments

Clinic Roundup

No Abstract (BioWorld Today, BioWorld-Today-2006-08-10) ...

BioWorld Today - Staff - 2006-08-10 00:00 - 0 comments - 0 attachments